default author photo

Jennifer M. Johnson

Thomas Jefferson University Hospital

111 South 11th Street,

Philadelphia, PA

United States

SCHOLARLY PAPERS

2

DOWNLOADS

152

TOTAL CITATIONS

5

Scholarly Papers (2)

1.

Durvalumab, Tremelimumab Alone or in Combination With Low-Dose or Hypofractionated Targeted Radiotherapy in Metastatic Non-Small Cell Lung Cancer Refractory to Prior PD-1 Therapy: A Multicentre, Open-Label, Randomized, Phase 2 Trial

Number of pages: 44 Posted: 13 Sep 2021
Harvard University - Brigham and Women's HospitalHarvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Massachusetts Institute of Technology and Harvard University - Broad Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of Virginia, Mayo Clinic, Duke University - Duke Cancer Institute, Rutgers University, New Brunswick - Rutgers Cancer Institute of New Jersey, University of Wisconsin School of Medicine, Cleveland Clinic, Thomas Jefferson University Hospital, Siteman Cancer Center, University of Pittsburgh - Medical Center (UPMC), Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, Government of the Italian Republic (Italy) - National Cancer Institute, Massachusetts Institute of Technology and Harvard University - Broad Institute, Massachusetts Institute of Technology and Harvard University - Broad Institute, Massachusetts Institute of Technology and Harvard University - Broad Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Dana-Farber Cancer Institute - Department of Data Science, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Harvard University - Dana-Farber Cancer Institute, Government of the United States of America - National Cancer Institute, Harvard University - Dana-Farber Cancer Institute, University of California, Davis - Department of Radiation Oncology and Harvard University - Melanoma Center
Downloads 93 (725,554)
Citation 5

Abstract:

Loading...

2.

A Multicenter Retrospective Analysis of Recurrent/Metastatic Nasopharyngeal Cancer from Non-Endemic Areas: Results in the Pre-Immunotherapy Era

Number of pages: 15 Posted: 03 May 2025
affiliation not provided to SSRN, University of Brescia, Fondazione IRCCS Istituto Nazionale dei Tumori - Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori - Department of Research, affiliation not provided to SSRN, affiliation not provided to SSRN, King Hussein Cancer Center (KHCC), University Hospital of Bellvitge - Bellvitge Biomedical Research Institute (IDIBELL), Acibadem MAA University School of Medicine - Department of Radiation Oncology, University of Piemonte Orientale, University of Genova, Azienda Ospedaliero-Universitaria Careggi, Hospital Duran i Reynals (ICO) - Catalan Institute of Oncology, Kuwait Cancer Control Centre - Radiation Oncology Department, Azienda Ospedaliera-Universitaria Pisana, Thomas Jefferson University, Thomas Jefferson University, University of Giessen - Faculty of Medicine, University Hospital of Modena - Radiation Oncology Unit, University of Brescia, University of Brescia, Thomas Jefferson University Hospital, AOU Città della Salute e della Scienza di Torino, Autonomous University of Barcelona - Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori - Head and Neck Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori and Humanitas University
Downloads 59 (970,490)

Abstract:

Loading...

Nasopharyngeal cancer, recurrence/metastasis, non-endemic areas, pre-immunotherapy outcomes